As of 25 April 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) for possible government financing. 

As such, the HTA Council hereby makes public its preliminary assessment that it does not recommend the government financing of ceftaroline fosamil for the treatment of community-acquired pneumonia (CAP) in the pediatric population, for stakeholder feedback/comments.

Kindly be apprised that the assessment on this health technology covers both the pediatric and adult population, but a separate recommendation will be released for the adult population after the completion of its assessment.

For the supporting evidence reviewed and discussed by the HTA Council in coming up with this preliminary recommendation, please refer to: https://tinyurl.com/EvidenceCeftaFosamilforPedia. All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 12 May 2025 (Monday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please do not hesitate to contact us through the same email address or via telephone call at (02) 8837 2071 loc. 4100.